Akebia Therapeutics (AKBA) Short Interest Ratio & Short Volume → Wall Street Legend Warns: 'A Strange Day Is Coming to America' (From Chaikin Analytics) (Ad) Free AKBA Stock Alerts $1.07 -0.03 (-2.73%) (As of 05/28/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Akebia Therapeutics Short Interest DataCurrent Short Interest11,700,000 sharesPrevious Short Interest11,860,000 sharesChange Vs. Previous Month-1.35%Dollar Volume Sold Short$13.81 millionShort Interest Ratio2.3 Days to CoverLast Record DateMay 15, 2024Outstanding Shares209,596,000 sharesPercentage of Shares Shorted5.58%Today's Trading Volume2,842,194 sharesAverage Trading Volume3,987,207 sharesToday's Volume Vs. Average71% Short Selling Akebia Therapeutics ? Sign up to receive the latest short interest report for Akebia Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartAKBA Short Interest Over TimeAKBA Days to Cover Over TimeAKBA Percentage of Float Shorted Over Time Ad Chaikin AnalyticsWall Street Legend Warns: "A Strange Day Is Coming to America"Get Your Cash Out of U.S. Banks Immediately Man who predicted 2023 bank run warns a historic financial reset is coming. Get out of cash and into a new vehicle 50 years in the making.Click here to learn more. Akebia Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/202411,700,000 shares $13.81 million -1.4%N/A2.3 $1.18 4/30/202411,860,000 shares $14.94 million -13.4%N/A2.4 $1.26 4/15/202413,690,000 shares $19.03 million +2.2%N/A2.9 $1.39 3/31/202413,400,000 shares $24.52 million +32.3%N/A3 $1.83 3/15/202410,130,000 shares $17.22 million +24.9%N/A3.4 $1.70 2/29/20248,110,000 shares $12.81 million +1.4%N/A4 $1.58 Get the Latest News and Ratings for AKBA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/20248,000,000 shares $11.76 million -8.9%N/A4.5 $1.47 1/31/20248,780,000 shares $14.75 million +12.1%N/A5.4 $1.68 1/15/20247,830,000 shares $12.14 million -0.5%N/A5 $1.55 12/31/20237,870,000 shares $9.76 million +7.4%N/A5.3 $1.24 12/15/20237,330,000 shares $8.43 million -18.7%N/A5.5 $1.15 11/30/20239,010,000 shares $9.55 million -8.8%N/A6.9 $1.06 11/15/20239,880,000 shares $9.88 million -4.3%N/A6.8 $1.00 10/31/202310,320,000 shares $9.08 million +33.2%N/A6.8 $0.88 10/15/20237,750,000 shares $7.03 million +6.5%N/A4.5 $0.91 9/30/20237,280,000 shares $8.30 million +0.7%N/A4.4 $1.14 9/15/20237,230,000 shares $9.11 million +24.4%N/A4.1 $1.26 8/31/20235,810,000 shares $8.08 million -14.1%N/A3.1 $1.39 8/15/20236,760,000 shares $8.86 million +10.3%N/A3.2 $1.31 7/31/20236,130,000 shares $10.24 million +13.7%N/A2.8 $1.67 7/15/20235,390,000 shares $5.71 million +11.4%N/A2.9 $1.06 6/30/20234,840,000 shares $4.43 million +11.3%N/A2.7 $0.92 6/15/20234,350,000 shares $4.96 million -15.5%N/A2.5 $1.14 5/31/20235,150,000 shares $5.36 million +26.5%N/A3 $1.04 5/15/20234,070,000 shares $4.44 million -9.6%N/A2.4 $1.09 4/30/20234,500,000 shares $4.09 million -20.8%N/A2.4 $0.91 4/15/20235,680,000 shares $3.57 million +0.4%N/A2.9 $0.63 3/31/20235,660,000 shares $3.17 million -15.3%N/A2.8 $0.56 3/15/20236,680,000 shares $4.49 million -20.3%N/A3 $0.67 2/28/20238,380,000 shares $7.06 million +82.6%N/A3.5 $0.84 2/15/20234,590,000 shares $4.07 million +38.3%N/A2 $0.89 1/31/20233,320,000 shares $2.09 million -28.1%N/A1.7 $0.63 1/15/20234,620,000 shares $3.21 million -0.9%N/A2.7 $0.70 12/30/20224,660,000 shares $2.69 million -0.4%N/A2.7 $0.58 12/15/20224,680,000 shares $2.12 million -2.9%N/A3.1 $0.45 11/30/20224,820,000 shares $1.30 million -12.5%N/A3.4 $0.27 11/15/20225,510,000 shares $1.41 million -6.9%N/A3.8 $0.26 10/31/20225,920,000 shares $1.51 million -5.9%N/A3.4 $0.25 10/15/20226,290,000 shares $1.82 million -13.4%N/A2.7 $0.29 9/30/20227,260,000 shares $2.30 million -5.8%N/A2.6 $0.32Must-See: Elon’s New Invention is Absolutely Insane (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… 9/15/20227,710,000 shares $2.85 million -3.5%N/A1.1 $0.37 8/31/20227,990,000 shares $2.91 million -14.5%N/A1 $0.36 8/15/20229,340,000 shares $3.87 million -18.5%N/A1 $0.41 7/31/202211,460,000 shares $4.48 million +1.4%N/A1.1 $0.39 7/15/202211,300,000 shares $4.77 million +19.5%N/A1 $0.42 6/30/20229,460,000 shares $3.34 million -39.6%N/A0.7 $0.35 6/15/202215,660,000 shares $5.53 million -11.9%N/A1.2 $0.35 5/31/202217,780,000 shares $6.58 million -8.1%N/A1.5 $0.37 5/15/202219,340,000 shares $8.68 million +1.2%N/A1.8 $0.45 4/30/202219,120,000 shares $7.94 million +12.3%N/A1.9 $0.42 4/15/202217,020,000 shares $9.16 million -20.5%N/A1.9 $0.54 3/31/202221,410,000 shares $15.37 million +44.1%N/A3 $0.72 3/15/202214,860,000 shares $34.18 million +12.9%N/A3.8 $2.30 2/28/202213,160,000 shares $28.43 million +7.6%N/A3.5 $2.16 2/15/202212,230,000 shares $22.38 million +9.0%N/A3.6 $1.83 1/31/202211,220,000 shares $22.33 million +9.9%N/A3.5 $1.99 1/15/202210,210,000 shares $22.46 million -10.0%N/A3.4 $2.20 12/31/202111,350,000 shares $25.65 million -4.2%N/A4.1 $2.26 12/15/202111,850,000 shares $29.03 million +4.1%N/A4.6 $2.45 11/30/202111,380,000 shares $30.84 million +10.3%N/A5.5 $2.71 11/15/202110,320,000 shares $29.62 million -11.2%N/A5.1 $2.87 10/29/202111,620,000 shares $33.35 million +1.9%N/A5.8 $2.87 10/15/202111,400,000 shares $32.49 million -10.2%N/A5.3 $2.85 9/30/202112,690,000 shares $36.55 million +1.5%N/A4.1 $2.88 9/15/202112,500,000 shares $34.75 million -6.6%N/A3.9 $2.78 8/31/202113,380,000 shares $39.34 million +2.8%N/A3.7 $2.94 8/13/202113,010,000 shares $32.79 million -6.9%N/A3.4 $2.52 7/30/202113,980,000 shares $34.53 million -11.0%N/A3.6 $2.47 7/15/202115,700,000 shares $52.12 million +2.9%10.3%4.1 $3.32 6/30/202115,260,000 shares $57.84 million -2.2%10.0%4.6 $3.79 6/15/202115,610,000 shares $54.95 million -3.0%10.2%4.5 $3.52 5/28/202116,090,000 shares $56.48 million -11.7%10.6%4.5 $3.51 5/14/202118,220,000 shares $60.67 million -0.3%N/A4.3 $3.33 4/30/202118,280,000 shares $59.41 million -7.2%N/A3.6 $3.25 4/15/202119,690,000 shares $61.33 million -7.6%N/A3.3 $3.12 3/31/202121,300,000 shares $65.92 million -15.2%N/A3.3 $3.10 3/15/202125,130,000 shares $90.72 million -1.5%N/A3.7 $3.61 2/26/202125,500,000 shares $88.49 million -3.2%N/A3.7 $3.47 2/12/202126,350,000 shares $125.69 million -4.0%N/A4 $4.77 1/29/202127,450,000 shares $94.02 million -4.8%N/A4.4 $3.43 1/15/202128,820,000 shares $91.36 million +0.5%N/A4.5 $3.17 12/31/202028,680,000 shares $85.75 million +20.9%N/A4.4 $2.99 12/15/202023,730,000 shares $75.46 million +0.8%N/A3.7 $3.18 11/30/202023,540,000 shares $79.80 million -6.2%N/A3.3 $3.39 11/15/202025,100,000 shares $63.75 million -6.1%N/A3 $2.54 10/30/202026,730,000 shares $60.68 million +7.7%N/A3.4 $2.27 10/15/202024,830,000 shares $88.89 million +12.0%N/A3.7 $3.58 9/30/202022,170,000 shares $55.65 million +141.8%N/A4.3 $2.51 9/15/20209,170,000 shares $24.21 million +12.4%N/A2 $2.64 8/31/20208,160,000 shares $84.95 million -10.0%N/A2.4 $10.41Must-See: Elon’s New Invention is Absolutely Insane (Ad)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.Click here for the full story… 8/14/20209,070,000 shares $95.51 million -5.2%N/A6.9 $10.53 7/31/20209,570,000 shares $106.90 million -1.8%N/A6.5 $11.17 7/15/20209,740,000 shares $120.29 million +1.0%N/A5.6 $12.35 6/30/20209,640,000 shares $122.43 million +61.5%N/A5.5 $12.70 6/15/20205,970,000 shares $72.42 million +18.5%N/A3.7 $12.13 5/29/20205,040,000 shares $58.67 million -21.3%N/A3 $11.64 5/15/20206,400,000 shares $79.49 million -16.0%N/A3.7 $12.42 4/30/20207,620,000 shares $61.72 million +3.8%N/A4.6 $8.10 4/15/20207,340,000 shares $53.36 million +8.3%N/A5.3 $7.27 3/31/20206,780,000 shares $52.27 million -6.5%5.8%4.4 $7.71 3/13/20207,251,800 shares $50.76 million -2.4%7.0%4.2 $7.00 2/28/20207,430,000 shares $46.29 million -5.6%7.2%5.3 $6.23 2/14/20207,870,000 shares $58.47 million -9.5%7.3%5 $7.43 1/31/20208,700,000 shares $76.82 million -6.9%8.2%5.4 $8.83 1/15/20209,340,000 shares $84.71 million -5.1%8.8%6.3 $9.07 12/31/20199,840,000 shares $78.03 million -4.4%9.3%7.6 $7.93 AKBA Short Interest - Frequently Asked Questions What is Akebia Therapeutics' current short interest? Short interest is the volume of Akebia Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 11,700,000 shares of AKBA short. Learn More on Akebia Therapeutics' current short interest. What is a good short interest ratio for Akebia Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AKBA shares currently have a short interest ratio of 2.0. Learn More on Akebia Therapeutics's short interest ratio. Which institutional investors are shorting Akebia Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Akebia Therapeutics: Torno Capital LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Akebia Therapeutics' short interest increasing or decreasing? Akebia Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 11,700,000 shares, a decline of 1.3% from the previous total of 11,860,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Akebia Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Akebia Therapeutics: G1 Therapeutics, Inc. (6.87%), Aldeyra Therapeutics, Inc (3.97%), Design Therapeutics, Inc. (8.59%), uniQure (5.66%), Eliem Therapeutics, Inc. (0.66%), Pyxis Oncology, Inc. (4.16%), Generation Bio Co. (3.34%), 2seventy bio, Inc. (13.22%), Prelude Therapeutics Incorporated (2.35%), Ovid Therapeutics Inc. (4.95%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Akebia Therapeutics stock? Short selling AKBA is an investing strategy that aims to generate trading profit from Akebia Therapeutics as its price is falling. AKBA shares are trading down $0.07 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Akebia Therapeutics? A short squeeze for Akebia Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AKBA, which in turn drives the price of the stock up even further. How often is Akebia Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AKBA, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: GTHX Short Interest Data ALDX Short Interest Data DSGN Short Interest Data QURE Short Interest Data ELYM Short Interest Data PYXS Short Interest Data GBIO Short Interest Data TSVT Short Interest Data PRLD Short Interest Data OVID Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AKBA) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy SykesElon’s New Device is About to Shock the WorldInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe #1 Crypto for AIWeiss RatingsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaDigitizing the $11T commodities sector with one tiny stockResource Stock DigestMusk, Bezos, and Gates All On Board… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.